Increased thirst and vasopressin secretion after myocardial infarction in rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  De Smet, H R ^a   Menadue, M F ^b   Oliver, J R ^b   Phillips, P A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Atrial natriuretic peptide; Heart failure

Indexed keywords

ATRIAL NATRIURETIC FACTOR; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLUID BALANCE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEMATOCRIT; HYPONATREMIA; LUNG EDEMA; NEUROMODULATION; NONHUMAN; OSMORECEPTOR; PLASMA RENIN ACTIVITY; PRESSORECEPTOR; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; THIRST; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; WATER DEPRIVATION;

EID: 0142063555     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00098.2003     Document Type: Article

References (31)

1. Blyth FM, Lazarus R, Ross D, Price M, Cheuk G, and Leeder SR. Burden and outcomes of hospitalisation for congestive heart failure. Med J Aust 167: 67-70, 1997.
2. Burrell LM, Chan RK, Phillips PA, Calafiore P, Tonkin AM, and Johnston CI. Echocardiographic assessment of left ventricular function in a rat model of heart failure. Clin Exp Pharmacol Physiol 23: 570-572, 1996.
3. Burrell LM, Palmer JM, and Baylis PH. Atrial natriuretic peptide inhibits fluid intake in hyperosmolar subjects. Clin Sci 83: 35-39, 1992.
4. Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, and Johnston CI. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol Heart Circ Physiol 275: H176-H182, 1998.
5. De Torrente A, Robertson GL, McDonald KM, and Schrier RW. Mechanisms of diuretic response to increased left atrial pressure in anesthetized dog. Kidney Int 8: 355-361, 1975.
6. Fater DC, Schultz HD, Sundet WD, Mapes HS, and Goetz KL. Effects of left atrial stretch in cardiac-denervated and intact conscious dogs. Am J Physiol Heart Circ Physiol 242: H1056-H1064, 1982.
7. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, and Johnson AK. Heart failure and the brain: new perspectives. Am J Physiol Regul Integr Comp Physiol 284: R259-R276, 2003.
8. Fitzsimons JT. Thirst and Sodium Appetite. Cambridge: Cambridge Univ. Press, 1979. (Monogr Physiol Soc 35)
9. Fitzimons JT. Angiotensin, thirst and sodium appetite. Physiol Rev 78: 583-686, 1998.
10. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang Kubo SH C, Rudin-Toretsky E, and Yusuf S for the SOLVD investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without heart failure. Circulation 82: 1724-1729, 1990.
11. Francis J, Wei SG, Weiss RM, Beltz T, Johnson AK, and Felder RB. Forebrain-mediated adaptations to myocardial infarction in the rat. Am J Physiol Heart Circ Physiol 282: H1898-H1906, 2002.
12. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, and Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 281: H2241-H2251, 2001.
13. Gheorghiade M and Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97: 282-289, 1998.
14. Kalra PR, Anker SD, and Coats AJS. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 51: 495-509, 2001.
15. Kim JK, Michel JB, Soubrier F, Durr J, Corvol P, and Schrier RW. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int 38: 818-822, 1990.
16. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, and Schrier RW. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 secretion in patients with chronic heart failure. J Am Soc Nephrol 10: 2165-2170, 1999.
17. McMurray JJ and Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83: 596-602, 2000.
18. Moore-Gillon MJ and Fitzimons JT. Pulmonary vein-atrial junction stretch receptors and the inhibition of drinking. Am J Physiol Regul Integr Comp Physiol 242: R452-R457, 1982.
19. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, and Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol Heart Circ Physiol 267: H2245-H2254, 1994.
20. Nishikimi T, Kawano Y, Saito Y, and Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27: 275-282, 1996.
21. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20: 248-252, 1992.
22. Palm C, Reimann D, and Gross P. The role of vasopressin antagonists in hyponatremia. Cardiovasc Res 51: 403-408, 2001.
23. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, and Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 44: 503-512, 1979.
24. Shen YT, Cowley AW, and Vatner SF. Relative roles of cardiac and arterial baroreceptors in vasopressin regulation during hemorrhage in conscious dogs. Circ Res 68: 1422-1436, 1991.
25. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, and Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305: 263-266, 1981.
26. Thrasher TN, Keil LC, and Ramsay DJ. Hemodynamic, hormonal and drinking responses to reduced venous return in the dog. Am J Physiol Regul Integr Comp Physiol 243: R354-R362, 1982.
27. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Selaru P, Chanoine F, Pressler ML, and Konstam MA. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423, 2001.
28. Williams TDM, Walsh KP, Lightman SL, and Sutton R. Atrial natriuretic peptide inhibits postural release of renin and vasopressin in humans. Am J Physiol Regul Integr Comp Physiol 255: R368-R372, 1988.
29. Wong LL and Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res 51: 391-402, 2001.
30. Xu DL, Martin PY, Ohara M, St. John J, Pattison T, Meng X, Morris K, Kim JK, and Schrier RW. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99: 1500-1505, 1997.
31. Yamani M and Massie BM. Congestive heart failure: insights from epidemiology, implications for treatment. Mayo Clin Proc 68: 1214-1218, 1993.